CVR Canadian Oil Recovery and Remediation Enterprises Ltd

Thallion Pharmaceuticals Inc. ("Thallion") (TSX VENTURE:TLN) and BELLUS Health
Inc. (TSX:BLU) ("BELLUS Health") announced today that in accordance with the
acquisition agreement dated June 17, 2013, as amended (the "Acquisition
Agreement") pertaining to the proposed plan of arrangement (the "Arrangement")
involving the acquisition of Thallion by BELLUS Health, Thallion has delivered a
notice to BELLUS Health indicating that Thallion has negotiated a final and
binding agreement with Iberville Development Leasing Limited pursuant to which
the latter has agreed to fully, finally and irrevocably release Thallion from
its obligations under the lease dated December 2, 2010, in exchange for the
payment of an amount which is less than the provision for the termination of
such lease included in the minimum net cash component announced on August 2,
2013. The cash component of the consideration payable on the effectiveness of
the Arrangement has been increased by $0.0124 per common share resulting in the
cash component of the consideration to be received by Thallion's shareholders on
the effectiveness of the Arrangement being $0.1889 per common share.


In addition to the cash component of the consideration, the Arrangement also
provides for the issuance of one contingent value right ("CVR") per common
share, entitling the holder thereof to: (A) its pro rata share of 100% of any
additional purchase price consideration to be received from Premium Brands
Holding Corp. in 2016 (representing up to a possible $0.0404 per CVR), (B) its
pro rata share of 5% of the Shigamabs(R) revenue generated or received by BELLUS
Health, capped at $6.5 million (or $0.1812 per CVR), and (C) its pro rata share
of 100% of any net proceeds generated from the licensing, selling or otherwise
commercializing of (i) diagnostic products or services using certain Caprion
Proteomics Inc. products, and (ii) all issued patents or pending patents
pertaining to such Caprion Proteomics Inc. products, in respect of which
Thallion has an ownership interest or monetary entitlement.


Subject to approval of the Arrangement by the Superior Court of Quebec and the
satisfaction of certain other closing conditions, it is now expected that the
Arrangement will take effect on or about August 15, 2013.


About Thallion (www.thallion.com)

Thallion is a biotechnology company developing pharmaceutical products in the
areas of infectious disease and oncology. Thallion's lead clinical program
Shigamabs(R) is a dual antibody product for the treatment of Shiga
toxin-producing E. coli bacterial infections and has recently completed a Phase
II clinical trial. Additional information about Thallion can be obtained at
www.thallion.com. 


About BELLUS Health (www.bellushealth.com)

BELLUS Health is a development-focused healthcare company concentrating on
products that provide innovative health solutions and address critical unmet
medical needs. The Company's lead program is KIACTA(TM), a novel drug candidate
currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis,
an orphan indication resulting in renal dysfunction that often rapidly leads to
dialysis and death. KIACTA(TM) is partnered with global private equity firm
Auven Therapeutics. AA amyloidosis affects approximately 35,000 to 50,000
individuals in the United States, Europe and Japan. 


Forward-Looking Statements

Certain statements contained in this news release, other than statements of fact
that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and uncertainties,
known and unknown, many of which are beyond the control of BELLUS Health Inc. or
Thallion Pharmaceuticals Inc. Such risks include but are not limited to: the
ability to obtain Court and regulatory approvals, third party consents and to
satisfy other closing conditions, risks relating to the satisfaction of payment
conditions under the CVRs, the ability to obtain financing, the impact of
general economic conditions, general conditions in the pharmaceutical and/or
nutraceutical industry, changes in the regulatory environment in the
jurisdictions in which the BELLUS Health Inc. and Thallion Pharmaceuticals Inc.
do business, stock market volatility, fluctuations in costs, changes to the
competitive environment due to consolidation, achievement of forecasted burn
rate, achievement of forecasted clinical trial milestones, and that actual
results may vary once the final and quality-controlled verification of data and
analyses has been completed. Consequently, actual future results may differ
materially from the anticipated results expressed in the forward-looking
statements, and there can be no assurance that any amounts will become payable
under the CVRs. The reader should not place undue reliance, if any, on any
forward-looking statements included in this news release. These statements speak
only as of the date made and neither BELLUS Health Inc. nor Thallion
Pharmaceuticals Inc. is under any obligation to update or revise such statements
as a result of any event, circumstances or otherwise, and BELLUS Health Inc. and
Thallion Pharmaceuticals Inc. disavow any intention to do so, unless required by
applicable legislation or regulation. Please see the public fillings of BELLUS
Health Inc. and Thallion Pharmaceuticals Inc., including the Annual Information
Form of BELLUS Health Inc. for further risk factors that might affect both
companies and their respective businesses.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
BELLUS Health Contact:
TMX Equicom
Adam Peeler
416-815-0700 ext. 225
apeeler@tmxequicom.com


Thallion Contact:
Michael Singer
Chief Financial Officer
(514) 940-3600
(514) 336-2343 (FAX)
info@thallion.com
www.thallion.com

Grafico Azioni Canadian Oil Recovery an... (TSXV:CVR)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Canadian Oil Recovery an... (TSXV:CVR)
Storico
Da Giu 2023 a Giu 2024